JPRN-jRCTs031210287已完成未知
A study to evaluate the effects of Biofermin tablets on bowel management in elderly patients requiring long-term care
Maruyama Michio0 个研究点目标入组 40 人开始时间: 2021年8月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 65age old 至 ot applicable（—）
- 性别
- All
入选标准
- •The elderly over 65 years old.
- •Patients who cannot defecate by themselves,requiring defecation assistance.
- •Patients who can take nutrition and drugs orally or by tube at the time of enrollment.
- •Patients who have less than 3 spontaneous bowel movements per week during the pre-observation period.
- •Patients who receive defecation treatment or additional laxatives at least once a week during the pre-observation period.
- •Patients who can provide the written consent for participation in this study. However,if the consent cannot be obtained by the patient,it is possible to obtain consent from a legally acceptable representative.
排除标准
- •Patients who have been pointed out to have organic abnormalities in the digestive tract.
- •Patients with serious complications.
- •Patients with infectious diseases.
- •Patients with active malignant tumors.
- •Patients who are allergic to intestinal medicine.
- •Patients who took probiotic products within two weeks before enrollment.
- •Patients who took opioid analgesics within two weeks before enrollment.
- •Patients who have been using psychiatric drugs for the treatment of psychiatric disorders, except for the use of sleeping pills or psychotropic drugs as needed.
- •Patients who took antibacterial agents within two weeks before enrollment.
- •Patients who started the new drug administration within two weeks before enrollment.
- •Patients who are inadequate to be enrolled in the study judged by the investigator.
研究者
相似试验
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)EUCTR2018-000462-11-ESBristol-Myers Squibb International Corporation250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-BEBristol-Myers Squibb International Corporation250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab incombination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer(NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer(NSCLC)MedDRA version: 20.0Level: LLTClassification code 10007096Term: Cancer of lungSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-ROBristol-Myers Squibb International Corporation250
已完成
2 期
An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)10038666Non-small cell lung cancerNL-OMON55382Bristol-Myers Squibb10